Deals · Updated 21 Oct, 02:05 am IST
OpenAI acquires biotech software startup Orchestra Bio
Why it matters for readers: It explains why AI companies are expanding into biotech and how that could speed up research operations.
- Orchestra Bio makes AI agents that help biotech companies manage tasks in drug discovery, including finances and clinical trial scheduling.1
- OpenAI said it will add Orchestra’s team and technology to its Rosalind model and the Rosalind Workbench tool for life sciences research.1
- Orchestra had raised around $20 million as of 2025 from investors including Andreessen Horowitz, Atria, and 8VC, and terms of the acquisition were not disclosed.1
- OpenAI already counts life‑science customers for Rosalind, such as Moderna and Novo Nordisk.1
Get a brief like this every morning
Uzha reads hundreds of sources and gives you the stories that matter for your work, with every source linked. Free.
Get started